VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report published on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 4.2 %

Shares of VBIV opened at $0.57 on Friday. The company has a market cap of $16.32 million, a PE ratio of -0.05 and a beta of 1.93. The business has a fifty day moving average of $0.61 and a 200 day moving average of $0.61. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $3.47.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.